Cancer immunotherapy

Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Lymphocyte, Cell cycle, Plasma, Marketing, Method, PCR, Amazon, Severe acute respiratory syndrome coronavirus 2, Knowledge, Research, Technology, TMB-2, TBIA, Neuron, Legislation, Cancer, Monocyte, Brain, Solution, Pressure, U.S. Securities and Exchange Commission, Synthase, Cancer immunotherapy, Neurodegeneration, Company, OTCQB, Alzheimer's disease, Biotechnology, Immune system, Apoptosis, Pharmaceutical industry, Medical imaging, Pharma

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.

Key Points: 
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe.
  • Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting

Retrieved on: 
Friday, November 11, 2022
China Media Group Headquarters, Transforming growth factor beta, DLT, Prevalence, Team Impulse, Nature, Mab, Syngenic, PK, Toxic epidermal necrolysis, Annual general meeting, Process, Immunotherapy, Research, Fucose, FIH, FCR, Adenocarcinoma, Neoplasm, TGF, Environment, Diagnosis, Primate, CDC, Cancer immunotherapy, HKEX, Interleukin 1 receptor, type II, PD-L1, News, Immunoglobulin G, Safety, IHC, PD-1, ICB, SITC, Social conditioning, Society for Immunotherapy of Cancer, Suzhou Industrial Park, Stomach, NK, Patient, Immune system, ADCC, Discovery, Therapy, FDA, Headquarters, Pharmaceutical industry, Vaccine, Medical imaging

SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022.

Key Points: 
  • SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022.
  • Claudin18.2 staining in 10% of the tumor cells at 1+ or above intensity was present in 216 (72%) tissue samples tested.
  • As of Aug 24, 2022, the first three dose cohorts have been completed and no DLT was observed.
  • Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular Disorders, Blister, Safety, Immunotherapy, FAQ, Alveolar soft part sarcoma, Senior, Company, Human, Conference, Security (finance), Drug Quality and Security Act, Review, Toxic epidermal necrolysis, Securities Act of 1933, RECIST, Poster, Cancer immunotherapy, U.S. Securities and Exchange Commission, DRAGON, Cancer, Neoplasm, Itch, A2, Patient, Social media, NSCLC, Gongshi, Investor, Publication, Private Securities Litigation Reform Act, Fibrosis, Risk, Rash, Partial, UC, Antibody, Clear cell renal cell carcinoma, Clinical trial, Growth, Society, MDSC, FDA, PD, AES, Head, Rock, Squamous cell carcinoma, MEL, File, Large-cell lung carcinoma, NASDAQ, Society for Immunotherapy of Cancer, Disease, SITC, Pharmaceutical industry, Medical imaging, Vaccine, Research, Part

These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.

Key Points: 
  • These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.
  • We are excited to continue advancing DRAGON and look forward to sharing additional data next year.
  • The biomarker strategy for DRAGON explores early signs of SRK-181 activity, including target engagement and pathway modulation.
  • The DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in patients with locally advanced or metastatic solid tumors is ongoing.

A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022

Retrieved on: 
Monday, November 7, 2022
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Molecule, Doctor of Philosophy, NYU, Patient, United Nations Scientific Committee on the Effects of Atomic Radiation, Tempus, Society for Immunotherapy of Cancer, Therapy, Neoplasm, NGS, CGMP, CEA, Section 32, Cell, Department, Consultant, HLA, Division, Immunotherapy, Annual general meeting, David Geffen School of Medicine at UCLA, Lung, Pancreatic cancer, UCLA, StepStone Group, MD Anderson Cancer Center, Oncology, Pancreatic Cancer Action, Medicine, Regent, Lung cancer, MSLN, Principal investigator, Cancer immunotherapy, Society, SITC, Poster, Mayo Clinic, Pharmaceutical industry, Medical imaging, Merck, MD, Schroders

Patients who may benefit from this therapy can be identified by using the Tempus diagnostic to pre-screen patients whose tumors have lost HLA-A*02.

Key Points: 
  • Patients who may benefit from this therapy can be identified by using the Tempus diagnostic to pre-screen patients whose tumors have lost HLA-A*02.
  • Once patients are identified, their T cells may be banked early in their disease course for potential utilization in a Phase 1 study in the event of relapse.
  • We are thrilled to enroll patients at BASECAMP-1 and get them prepped for potential inclusion in Phase 1 studies in 2023.
  • The Tmod mechanism utilizes two receptors to exploit common, specific gene losses in tumors that distinguish tumor from normal cells.

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

Retrieved on: 
Thursday, October 20, 2022
Degenerative disease, Society for Immunotherapy of Cancer, Merck, Molecular biology, Therapy, Government, Cancer immunotherapy, Conference, Global Partnership for Education, SITC, ENA, Patient, Annual Meetings of the International Monetary Fund and the World Bank Group, Drug development, METTL3, RNA, Enzyme, Annual general meeting, RME, Immunotherapy, Inflammation, Cancer, University, Trial of the century, Drug discovery, STORM, Industry, CEO, Merck Group, CNS, Environment, FTI, FDA, Human, IP Group, Pharmaceutical industry, Vaccine, IND

CAMBRIDGE, England, Oct. 20, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting novel data on its lead program STC-15, a first-in-class clinical candidate, at the upcoming 34th EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium and the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Dr. Jerry McMahon, CEO of STORM Therapeutics commented:"We are delighted to be presenting data from our first-in-class clinical candidate STC-15, an orally bioavailable, highly selective METTL3 inhibitor at these two scientific conferences.
  • There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.
  • STORM's lead program STC-15 is a first-in-class clinical candidate and will be the first inhibitor of RNA modification to enter clinical development in humans.
  • In addition, the meeting includes updates on major national and international initiatives coming from academia, government, and industry, as well as important society projects.

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

Retrieved on: 
Thursday, October 20, 2022
Degenerative disease, Society for Immunotherapy of Cancer, Merck, Molecular biology, Therapy, Government, Cancer immunotherapy, Conference, Global Partnership for Education, SITC, ENA, Patient, Annual Meetings of the International Monetary Fund and the World Bank Group, Drug development, METTL3, RNA, Enzyme, Annual general meeting, RME, Immunotherapy, Inflammation, Cancer, University, Trial of the century, Drug discovery, STORM, Industry, CEO, Merck Group, CNS, Environment, FTI, FDA, Human, IP Group, Pharmaceutical industry, Vaccine, IND

CAMBRIDGE, England, Oct. 20, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting novel data on its lead program STC-15, a first-in-class clinical candidate, at the upcoming 34th EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium and the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Dr. Jerry McMahon, CEO of STORM Therapeutics commented:"We are delighted to be presenting data from our first-in-class clinical candidate STC-15, an orally bioavailable, highly selective METTL3 inhibitor at these two scientific conferences.
  • There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.
  • STORM's lead program STC-15 is a first-in-class clinical candidate and will be the first inhibitor of RNA modification to enter clinical development in humans.
  • In addition, the meeting includes updates on major national and international initiatives coming from academia, government, and industry, as well as important society projects.

Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting

Retrieved on: 
Friday, October 14, 2022
News, CDC, Interleukin 1 receptor, type II, Therapy, Syngenic, Cancer immunotherapy, Science, SITC, FIH, China Media Group Headquarters, Primate, ICB, HKEX, Neoplasm, Patient, Social conditioning, Research, Fucose, Annual general meeting, Immunotherapy, Society for Immunotherapy of Cancer, Cancer, Process, FCR, Immune system, Discovery, Nature, 2021 Essex County Council election, Toxic epidermal necrolysis, EST, ADCC, Environment, NK, PK, Headquarters, PD-L1, FDA, Suzhou Industrial Park, Pharmaceutical industry, Vaccine

Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.

Key Points: 
  • Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.
  • Details of the poster presentations are as follows:
    Full text of the abstracts will be released on the SITC website at 8:00 a.m. EST, November 7, 2022, and the posters will be available on Transcenta's website ( https://www.transcenta.com/ ) on November 12, 2022.
  • Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.
  • Transcenta is developing ten therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer

Retrieved on: 
Monday, October 10, 2022
Health, General Health, LinkedIn, Nektar Therapeutics, Therapy, Hospital, GlaxoSmithKline, Growth, Acceleration, Drug, Patient, Drug development, Cancer immunotherapy, Internal medicine, Gilead Sciences, Cancer, Technology, University, Pharmacovigilance, Faculty, Hospital of the University of Pennsylvania, University of Colorado School of Medicine, Salk Institute for Biological Studies, Â, OV, Leadership, Pharmaceutical industry, Genentech

IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of Julia (Julie) Maltzman, M.D., as its Chief Medical Officer.

Key Points: 
  • IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of Julia (Julie) Maltzman, M.D., as its Chief Medical Officer.
  • At IconOVir, Dr. Maltzman will lead all activities associated with the clinical development of the IconOVirs emerging OV-based therapeutic pipeline, including clinical development, clinical operations, medical affairs and pharmacovigilance activities.
  • We are thrilled to welcome Julie to our team as we prepare to advance ICVB-1042, our lead product candidate, into first-in-human Phase 1 studies next year, said Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir.
  • Dr. Maltzman joins IconOVir from Genentech, where she most recently served as Franchise Head, Vice President and Global Head of Gastrointestinal (GI) and Cancer Immunotherapy.

Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™

Retrieved on: 
Tuesday, September 27, 2022
Virus, Legislation, Pressure, Lymphocyte, USD, Patient, MERS, U.S. Securities and Exchange Commission, Technology, TMB-2, CLIA, Research, Monocyte, PCR, Synthase, Adoption, COVID-19, Knowledge, LDT, Company, COVID, TBIA, Amazon, CAGR, Apoptosis, Severe acute respiratory syndrome coronavirus 2, OTCQB, CEO, Nursing, Method, School, GLOBE, IRB, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, Cancer immunotherapy, Brain, Quarantine, USPTO, Solution, Pathology, Biotechnology, Cell cycle, Neuron, Pharmaceutical industry, Vaccine, Online shopping, Medical imaging, Long COVID, Rotavirus, Pharma

The Company previously announced positive data on TolloTest in hospitalized and outpatient settings such as skilled nursing facilities and schools.

Key Points: 
  • The Company previously announced positive data on TolloTest in hospitalized and outpatient settings such as skilled nursing facilities and schools.
  • TolloTest is a potential companion biomarker test for the Companys 3CL protease inhibitor dietary supplement Tollovid and a companion diagnostic for its Phase 2 asset Tollovir for hospitalized COVID.
  • TolloTest is a diagnostic assay centered on identifyoing and quantifying the 3CL protease and its activity levels in order to be able to approximate active viral replication.
  • 3CL Pharma, through Todos brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir, while also developing the 3CL protease diagnostic TolloTest.

Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp

Retrieved on: 
Thursday, September 22, 2022
Adult, Duke Diet and Fitness Center, Virus, Legislation, Cliburn, Pressure, Redbox, Lymphocyte, USD, Patient, MERS, U.S. Securities and Exchange Commission, Technology, Lowe's Market, TMB-2, Todos, Research, Candy, Monocyte, PCR, Synthase, COVID-19, Knowledge, CBD, Company, COVID, TBIA, Amazon, CAGR, Apoptosis, University, TEL, Severe acute respiratory syndrome coronavirus 2, OTCQB, Travel, CEO, Method, GLOBE, IRB, Airport, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, Southwestern United States, Cancer immunotherapy, Brain, Intelligence, Solution, Biotechnology, Cell cycle, Overalls, Awareness, Neuron, Retail, Online shopping, Pharmaceutical industry, Medical imaging, Pharma

The new Tollovid and CBD products for the AI Retail machines will be manufactured in different adult and pediatric formulations in the Todos newly leased Cleburn, Texas-based facility.

Key Points: 
  • The new Tollovid and CBD products for the AI Retail machines will be manufactured in different adult and pediatric formulations in the Todos newly leased Cleburn, Texas-based facility.
  • Todos anticipates $11.5 million in revenue in the fourth quarter of 2022 from this contract as Nerd Hemp commences its nationwide rollout.
  • Nerd Hemp was founded in 2019 with a focus on launching CBD products to the marketplace through automated retail (AI Retail) machines.
  • Nerd Hemp intends to launch its CBD AI Retail machines in retail locations nationwide through its strategic distribution channels.